ConductScience.org, home

Comparison · NCT02731638-sae

Intrastromal Voriconazole Plus Natamycin vs Natamycin Alone: serious adverse events

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Intrastromal Voriconazole Plus Natamycin vs Natamycin Alone: serious adverse events. Trial comparisons, record NCT02731638-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02731638-sae

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 100.000000000000000006940.0989wilson
Risk in group 200.000000000000000006940.0989wilson
Risk difference, group 1 minus group 20-0.09890.0989newcombe hybrid score
Risk ratio, group 1 over group 2loga group has no participants with the outcome
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zero
Number needed to harmfrom the risk difference intervalthe two groups' risks are equal

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Intrastromal Voriconazole Plus Natamycin
Intrastromal voriconazole plus standard of care topical treatment for fungal keratitis~Intrastromal voriconazole: Subjects will receive three intrastromal voriconazole injections over 10 days. Intrastromal voriconazole injection is a routine procedure performed by Aravind Eye Hospital for fungal keratitis.~Natamycin: Subjects will receive topical 5% natamycin drops hourly for 3 days.
035EG000
Group 2Natamycin AloneStandard of care topical treatment for fungal keratitis~Natamycin: Subjects will receive topical 5% natamycin drops hourly for 3 days.035EG001

Harm

What it counts
Total, serious adverse events
Time frame
3 months

Source ClinicalTrials.gov

Trial

Title
Mycotic Antimicrobial Localized Injection for Treatment of Corneal Ulcers
NCT number
NCT02731638
Phases
PHASE3
Conditions
Corneal Ulcer, Fungal Keratitis
Interventions
Intrastromal voriconazole, Natamycin
Lead sponsor
University of California, San Francisco
Results first posted
2019-10-01

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT02731638-sae